Pro-apoptotic function of calsenilin/DREAM/KChIP3.

Apoptotic cell death and increased production of amyloid b peptide (Ab) are pathological features of Alzheimer's disease (AD), although the exact contribution of apoptosis to the pathogenesis of the disease remains unclear. Here we describe a novel pro-apoptotic function of calsenilin/DREAM/KChIP3. By antisense oligonucleotide-induced inhibition of calsenilin/DREAM/KChIP3 synthesis, apoptosis induced by Fas, Ca2+-ionophore, or thapsigargin is attenuated. Conversely, calsenilin/DREAM/KChIP3 expression induced the morphological and biochemical features of apoptosis, including cell shrinkage, DNA laddering, and caspase activation. Calsenilin/DREAM/KChIP3-induced apoptosis was suppressed by caspase inhibitor Z-VAD and by Bcl-XL, and was potentiated by increasing cytosolic Ca2+, expression of Swedish amyloid precursor protein mutant (APPSW) or presenilin 2 (PS2), but not by a PS2 deletion lacking its C-terminus (PS2/411stop). In addition, calsenilin/DREAM/KChIP3 expression increased Ab42 production in cells expressing APPsw, which was potentiated by PS2, but not by PS2/411stop, which suggests a role for apoptosis-associated Ab42 production of calsenilin/DREAM/KChIP3.     

人源性基因calsenilin/KChIP3/DREAM的单克隆抗体的制备及鉴定

Calsenilin/KChIP3/DREAM, 是脑中高表达蛋白,最初发现是因其与presenilin 和钙离子结合而得名。作为转录因子抑制因子,该基因在细胞核内具有多种功能。该基因在钙离子作用下细胞核内常常与c-fos、prodynorphin等基因的启动子下游的特异性DRE位点相结合,调节这些基因的表达。另一方面,作为钾离子通道结合蛋白,该基因具有4种isoforms,其中KChIP1广泛存在于各种组织中而KChIP2只在心脏中特异表达,KChIP3和 KChIP4则在脑中显示较高的表达。4种基因在C-端结构非常相象,N-端则显示多样性。除此之外,和许多基因相似,calsenilin经PKC、CKI、PKA等激酶作用可产生多位点的磷酸化,其中主要位点Ser63的磷酸化可以阻止caspase-3对该基因的降解作用。另一方面,Calsenilin作为转录因子激动因子结合于维生素D和视黄酸效应因子启动子上游促进转录的进行。 到目前为止,Calsenilin/KChIP3/DREAM在细胞核内具有双重基因表达调控作用,即当结合于启动子上游时显示正调控而当结合在启动子下游时显示负调控。为了更加深入研究calsenilin的功能及寻找新的受其调控的基因,首先制备可特异性识别的单克隆抗体。利用RT-PCR 技术,从人脑中提取RNA扩增calsenilin全基因,克隆于pGEX-4T-2原核细胞表达载体中,经IPTG诱导表达、Gluthathion Sepharose 4B纯化得到GST-calsenilin/DREAM/KChIP3重组蛋白,并免疫小鼠。通过PEG细胞融合得到单克隆抗体。经细胞免疫染色及Western blotting检测显示说明本实验得到单克隆抗体可以用来进行细胞免疫染色及Western blotting等检测。该抗体的成功制备,为今后对calsenilin/DREAM/KChIP3调控基因表达的更深入研究提供了有效工具,也填补了国内尚无该基因单克隆抗体资源的空白。     

A role for calsenilin and related proteins in multiple aspects of neuronal function

The protein variously called calsenilin, DREAM, or KChIP3 has been independently discovered three times, accounting for the three different names currently in use. Calsenilin appears to have three, perhaps independent, roles. Calsenilin binds and modulates some of the effects of the Alzheimer disease-related protein presenilin, while presenilin can modulate some of the effects of calsenilin. Calsenilin binds the dynorphin response element and regulates dynorphin expression, hence regulating nociception. Calsenilin binds Kv channels and modulates potassium conductance, playing a role in long-term potentiation as well as in other important plastic pathways. Other members of the calsenilin family share at least some of the roles. For example, KChIP1, KChIP2, and CALP can all bind presenilins and can all modulate A-type potassium channels. Further functional dissection of this family of proteins will provide insight into numerous aspects of neuronal function and will illuminate the role of the calsenilin family of proteins in disease.     

Palmitoylation of KChIP splicing variants is required for efficient cell surface expression of Kv4.3 channels

The Ca(2+)-binding proteins KChIP1-4 (KChIP3 is also known as DREAM and calsenilin) act as auxiliary subunits for voltage-gated K(+) channels in the Kv4 family. Here we identify three splicing isoforms of rat KChIP2 with variable N-terminal peptides. The two longer isoforms, which contain the 32-amino acid peptide, produce larger increases in Kv4.3 protein level and current density and more effectively localize themselves and their associated channels at the plasma membrane than the shortest variant. The 32-amino acid peptide contains potential palmitoylation cysteines. Metabolic labeling demonstrates that these cysteines in the KChIP2 isoforms, as well as the corresponding sites in KChIP3, are palmitoylated. Mutating these cysteines reduces their plasma membrane localization and the enhancement of Kv4.3 current density. Thus, palmitoylation of the KChIP auxiliary subunits controls plasma membrane localization of their associated channels.     

DREAM/Calsenilin/KChIP3:神经系统的多功能蛋白

新近发现的转录因子DREAM(downstreamregulatoryelementantagonistmodulator)可结合到基因(包括PPD、Hrk、cfos等)的DRE(downstreamregulatoryelement)位点,抑制基因转录。它是第一个已知的可以直接与DNA结合发挥转录抑制作用的Ca2 结合蛋白,为Ca2 调节基因表达除蛋白激酶/磷酸酶这条主要通路外提供了另一条通路。由于DREAM与另两个研究小组发现的蛋白calsenilin和KChIP3实为同一种物质,所以DREAM具有PS(presenilin)作用蛋白、Kv4通道调节蛋白和转录因子的多重功能特性。本文将就DREAM的分布、功能及其调控、DREAM与疼痛的关系作简要综述。     

The Potassium Channel Interacting Protein 3 (DREAM/KChIP3) Heterodimerizes with and Regulates Calmodulin Function

Downstream regulatory element antagonistic modulator (DREAM/KChIP3), a neuronal EF-hand protein, modulates pain, potassium channel activity, and binds presenilin 1. Using affinity capture of neuronal proteins by immobilized DREAM/KChIP3 in the presence and absence of calcium (Ca²⁺) followed by mass spectroscopic identification of interacting proteins, we demonstrate that in the presence of Ca²⁺, DREAM/KChIP3 interacts with the EF-hand protein, calmodulin (CaM). The interaction of DREAM/KChIP3 with CaM does not occur in the absence of Ca²⁺. In the absence of Ca²⁺, DREAM/KChIP3 binds the EF-hand protein, calcineurin subunit-B. Ca²⁺-bound DREAM/KChIP3 binds CaM with a dissociation constant of ∼3 μm as assessed by changes in DREAM/KChIP3 intrinsic protein fluorescence in the presence of CaM. Two-dimensional ¹H,¹⁵N heteronuclear single quantum coherence spectra reveal changes in chemical shifts and line broadening upon the addition of CaM to ¹⁵N DREAM/KChIP3. The amino-terminal portion of DREAM/KChIP3 is required for its binding to CaM because a construct of DREAM/KChIP3 lacking the first 94 amino-terminal residues fails to bind CaM as assessed by fluorescence spectroscopy. The addition of Ca²⁺-bound DREAM/KChIP3 increases the activation of calcineurin (CN) by calcium CaM. A DREAM/KChIP3 mutant incapable of binding Ca²⁺ also stimulates calmodulin-dependent CN activity. The shortened form of DREAM/KChIP3 lacking the NH₂-terminal amino acids fails to activate CN in the presence of calcium CaM. Our data demonstrate the interaction of DREAM/KChIP3 with the important EF-hand protein, CaM, and show that the interaction alters CN activity.     

Contribution of presenilin/gamma-secretase to calsenilin-mediated apoptosis

Mutant presenilins cause early-onset of familial Alzheimer's disease and render cells vulnerable to apoptosis. Calsenilin/DREAM/KChIP3 is a multifunctional calcium-binding protein that interacts with presenilin and mediates calcium-mediated apoptosis. In the present study, we report that the calsenilin-mediated apoptosis is regulated by presenilin. The expression of calsenilin was highly up-regulated in neuronal cells undergoing Abeta42-triggered cell death. The incidence of calsenilin-mediated apoptosis was diminished in presenilin-1(-/-) mouse embryonic fibroblast cells or neuronal cells stably expressing a loss-of-function presenilin-1 mutant. On the contrary, an array of familial Alzheimer's disease-associated presenilin mutants (gain-of-function) increased calsenilin-induced cell death. Moreover, gamma-secretase inhibitors, including compound E and DAPT, decreased the calsenilin-induced cell death. These results suggest that the pro-apoptotic activity of calsenilin coordinates with presenilin/gamma-secretase activity to play a crucial role in the neuronal death of Alzheimer's disease.     

Hyperglycemia induces early upregulation of the calcium sensor KChIP3/DREAM/calsenilin in the rat retina

Hyperglycemia alters the tight control of intracellular calcium dynamics in retinal cells and may lead to the development of diabetic retinopathy. The potassium channel interacting protein 3 (KChIP3) also known as DREAM (Downstream Regulatory Element Antagonist Modulator) or calsenilin (KChIP3/DREAM/calsenilin), a member of the neuronal calcium sensor protein family, is expressed in Müller glial cells and upregulated under high glucose experimental culture conditions. Here, we analyzed the expression and function of KChIP3 in the retina of streptozotocin induced diabetic Long Evans rats by immunofluorescence confocal microscopy, western blot, co-immunoprecipitation, whole cell patch clamp recording on isolated cells and KChIP3 gene silencing by RNA interference. Three weeks after streptozotocin application, KChIP3 was increased throughout the different retinal layers and this process was not linked to augmented apoptosis. KChIP3 co-immunoprecipitated with voltage gated K(+) channels of the K(V)4.2-4.3 subtype in retinal extracts from control and hyperglycemic rats. Electrophysiological analysis showed that control cells did not express A type (K(V)4-mediated) K(+) currents but most of the cells from streptozotocin treated retinas displayed macroscopic currents with an inactivating component sensitive to 4-AP, suggesting the persistence of the A type currents at early times after treatment. siRNA analysis in Müller cells cultures grown under high glucose experimental conditions corroborated that, when the expression of KChIP3 is 50% reduced, the number of cells expressing A type currents decreases significantly. Together these data suggest an altered expression and function of KChIP3 after streptozotocin induced hyperglycemia that might help explain some pathological alterations in early diabetic retinopathy.